Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?

Am J Hypertens. 2015 Feb;28(2):182-9. doi: 10.1093/ajh/hpu129. Epub 2014 Jul 13.

Abstract

Background: Hypertension is a common comorbidity in patients with chronic kidney disease (CKD). We reported earlier that oral anticoagulants, including warfarin and dabigatran, may induce acute kidney injury. No effects of oral anticoagulants on blood pressure (BP) have been previously reported. The aim of this study was to examine in detail the relationship of anticoagulant therapy and BP in rats.

Methods: Sham-operated and 5/6 nephrectomy rats were treated with different doses of oral anticoagulants (warfarin and dabigatran), superoxide scavenger N-acetylcysteine (NAC), vitamin K, and protease activated receptor 1 (PAR-1) inhibitor SCH79797. BP was measured by a tail cuff daily.

Results: Warfarin and dabigatran both increased systolic BP in sham-operated and 5/6 nephrectomy rats in a dose-dependent manner. SCH79797 also increased systolic BP in a dose-dependent manner. Vitamin K prevented warfarin-induced increase in BP but did not affect BP when administered alone. NAC delayed the warfarin-associated increase in BP. Warfarin effects on BP were similar in 5/6 nephrectomy rats with different CKD stages.

Conclusions: Both warfarin and dabigatran increase systolic BP in rats. The mechanism of this effect is not clear, but our data suggest that it is related to decreased thrombin activity associated with anticoagulant treatment. The superoxide scavenger NAC delayed, but did not prevent, warfarin-induced hypertension.

Keywords: 5/6 nephrectomy.; blood pressure; chronic kidney injury; dabigatran; hypertension; warfarin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Animals
  • Anticoagulants / pharmacology
  • Antifibrinolytic Agents / pharmacology
  • Antithrombins / pharmacology*
  • Benzimidazoles / pharmacology*
  • Blood Pressure / drug effects*
  • Dabigatran
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Free Radical Scavengers / pharmacology
  • Nephrectomy
  • Pyrroles / pharmacology
  • Quinazolines / pharmacology
  • Rats
  • Receptor, PAR-1 / antagonists & inhibitors
  • Renal Insufficiency, Chronic*
  • Vitamin K / pharmacology
  • Warfarin / pharmacology*
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacology

Substances

  • Anticoagulants
  • Antifibrinolytic Agents
  • Antithrombins
  • Benzimidazoles
  • Free Radical Scavengers
  • N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine
  • Pyrroles
  • Quinazolines
  • Receptor, PAR-1
  • beta-Alanine
  • Vitamin K
  • Warfarin
  • Dabigatran
  • Acetylcysteine